Multigene predictors in early-stage breast cancer: moving in or moving out?

References

• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Ross JS, Linette GP, Stec J et al. Breast cancer biomarkers and molecular medicine. Expert Rev. Mol. Diagn.3(5), 573–585 (2003).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst.98, 262–272 (2006).
   PubMed Web of Science ®Google Scholar
• Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin. Oncol.34, S10–S16 (2007).
   PubMed Web of Science ®Google Scholar
• Stec J, Wang J, Coombes K et al. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J. Mol. Diagn.7, 357–367 (2005).
   PubMed Web of Science ®Google Scholar
• Gruvberger-Saal SK, Cunliffe HE, Carr KM, Hedenfalk IA. Microarrays in breast cancer research and clinical practice – the future lies ahead. Endocr. Relat. Cancer13, 1017–1031 (2006).
   PubMed Web of Science ®Google Scholar
• Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin. Cancer Res.13, 2831–2835 (2007).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res.11, 5678–5685 (2005).
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. (2008) (Epub ahead of print).
   Google Scholar
• Whitehead CM, Nelson R, Hudson P et al. Selection and optimization of a panel of early stage breast cancer prognostic molecular markers. Modern Pathol.18, 55A (2006).
   Google Scholar
• Ring BZ, Seitz RS, Beck R et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol.24, 3039–3047 (2006).
   PubMed Web of Science ®Google Scholar
• Davis LM, Harris C, Tang L et al. Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. J. Mol. Diagn.9, 327–336 (2007).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N. Engl. J. Med.351, 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Tabesh B, Bitterman P et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res.11(24 Pt 1), 8623–8631 (2005).
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.25, 5287–5312 (2007).
   PubMed Web of Science ®Google Scholar
• Lo SS, Norton J, Mumby PB et al. Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(18S), 577 (2007).
   Google Scholar
• Sparano JA. TAILORx: Trial Assigning Individualized Options for Treatment (Rx). Clin. Breast Cancer7, 347–350 (2006).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Suman VJ, Ingle JN et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res.12, 2080–2087 (2006).
   PubMed Web of Science ®Google Scholar
• Garber K. Gene expression tests foretell breast cancer’s future. Science303, 1754–1755 (2007).
   Google Scholar
• Perreard L, Fan C, Quackenbush JF et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res.8, R23 (2006).
   Google Scholar
• Bogaerts J, Cardoso F, Buyse M et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat. Clin. Pract. Oncol.3, 540–551 (2006).
   PubMedGoogle Scholar
• Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet365, 671–679 (2005).
   PubMed Web of Science ®Google Scholar
• Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol.24, 1665–1671 (2006).
   PubMed Web of Science ®Google Scholar
• Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med.356, 217–226 (2007).
   PubMed Web of Science ®Google Scholar
• Ayers M, Symmans WF, Stec J et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol.22, 2284–2293 (2004).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Pusztai L, Delaloge S et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J. Clin. Oncol.23, 8331–8339 (2005).
   PubMedGoogle Scholar
• Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule associated protein (MAP)-tau: a novel mediator of paclitaxel sensitivity In Vitro and in vivo.Cell Cycle4, 1149–1152 (2005).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol.23, 9312–9318 (2005).
   PubMed Web of Science ®Google Scholar
• Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst.97, 30–39 (2005).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat.101, 113–121 (2007).
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Is molecular profiling ready for use in clinical decision making? Oncologist12, 301–311 (2007).
   PubMed Web of Science ®Google Scholar